ImmuPharma (LON:IMM) Stock Price Down 9.9% - Time to Sell?

Key Points

• ImmuPharma's stock price fell by 9.9%, trading as low as GBX 10.58 ($0.14) with an increase in trading volume of 72% compared to its average.
• The company reported a negative EPS of GBX (0.38) for the last quarter, with analysts predicting -339.00 EPS for the current fiscal year.
• ImmuPharma is focused on developing peptide-based therapeutics, particularly for autoimmune diseases, with its lead program, P140 (Lupuzor™), targeting Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price was down 9.9% during trading on Thursday . The stock traded as low as GBX 10.58 ($0.14) and last traded at GBX 10.90 ($0.15). Approximately 14,800,078 shares changed hands during trading, an increase of 72% from the average daily volume of 8,597,301 shares. The stock had previously closed at GBX 12.10 ($0.16).

ImmuPharma Stock Down 5.2%

The stock has a market capitalization of £52.61 million, a price-to-earnings ratio of -1,182.92 and a beta of 1.53. The company's 50-day simple moving average is GBX 4.84 and its 200 day simple moving average is GBX 3.44.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, equities analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.